Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial.

Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial. Clin Cardiol. 2016 Mar; 39(3):137-44.

View in: PubMed

subject areas

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Anticholesteremic Agents
Apolipoprotein B-100
Biomarkers
Cholesterol, LDL
Clinical Protocols
Double-Blind Method
Ezetimibe
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypercholesterolemia
Muscular Diseases
Proprotein Convertase 9
Research Design
Time Factors
Treatment Outcome